RNA-Binding Protein Expression Alters Upon Differentiation of Human B Cells and T Cells

Nordin D. Zandhuis1,2, Benoit P. Nicolet1,2 and Monika C. Wolkers1,2*

1 Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands, 2 Oncoide Institute, Utrecht, Netherlands

B cells and T cells are key players in the defence against infections and malignancies. To exert their function, B cells and T cells differentiate into effector and memory cells. Tight regulation of these differentiation processes is key to prevent their malfunction, which can result in life-threatening disease. Lymphocyte differentiation relies on the appropriate timing and dosage of regulatory molecules, and post-transcriptional gene regulation (PTR) is a key player herein. PTR includes the regulation through RNA-binding proteins (RBPs), which control the fate of RNA and its translation into proteins. To date, a comprehensive overview of the RBP expression throughout lymphocyte differentiation is lacking. Using transcriptome and proteome analyses, we here catalogued the RBP expression for human B cells and T cells. We observed that even though the overall RBP expression is conserved, the relative RBP expression is distinct between B cells and T cells. Differentiation into effector and memory cells alters the RBP expression, resulting into preferential expression of different classes of RBPs. For instance, whereas naive T cells express high levels of translation-regulating RBPs, effector T cells preferentially express RBPs that modulate mRNA stability. Lastly, we found that cytotoxic CD8+ and CD4+ T cells express a common RBP repertoire. Combined, our study reveals a cell type-specific and differentiation-dependent RBP expression landscape in human lymphocytes, which will help unravel the role of RBPs in lymphocyte function.

Keywords: RNA binding protein, T cells, B cells, B and T cell differentiation, T cell cytotoxicity, post transcriptional regulation (PTR)

INTRODUCTION

B cells and T cells are essential to eradicate microbial infections and malignant cells. Upon antigen recognition through their receptors, B cells produce antibodies and T cells produce cytokines and chemokines, respectively. Cytotoxic T cells also acquire the capacity to kill target cells. The critical contribution of these lymphocyte subsets to anti-microbial and anti-tumor responses was evidenced by the discovery of genetic mutations in humans that result in immune dysfunction in response to infections (1). Similarly, effective T cell responses are key for tumor immunosurveillance (2).

Importantly, tight regulation of B cell and T cell effector function is key for effective clearance of infections. The aberrant production of antibodies by B cells, and the overproduction of effector molecules by T cells has been correlated with several autoimmune disorders, including systemic
lupus erythematosus, rheumatoid arthritis and multiple sclerosis (3–6). Likewise, patients suffering from severe disease upon COVID-19 infection developed auto-antibodies against type-I interferons (7), and an excess cytokine production in COVID-19 patients can result in organ dysfunction (8). Conversely, in chronic HIV infections or in tumors, T cells gradually lose their capacity to produce effector cytokines and to kill target cells (9, 10). These findings combined highlight the necessity to fine-tune the effector function of B cells and T cells.

To perform their effector function, B cells and T cells need to undergo an intricate process of differentiation. B cells differentiate into antibody-producing plasmablasts in germinal centers (GC), and upon pathogen clearance into long-lived memory B cells. Likewise, upon T cell priming, T cells differentiate into effector T cells, and upon pathogen clearance are maintained as memory T cells to ensure long-term production from recurring infections. In the past decennia, important insights have been obtained how B cells and T cell differentiate. In particular, the role of transcription factors and of metabolic regulators was extensively studied (11–14).

For appropriate lymphocyte differentiation, the regulators of differentiation processes must be produced at the right time and the right amount. In fact, gene dosage of transcription factors was shown to be key for B cell and T cell differentiation (15–18). This fine-tuning of gene expression is - at least in part - regulated by post-transcriptional events governed by RNA-binding proteins (RBPs) and non-coding RNAs (19, 20). RBPs control a plethora of processes. They orchestrate RNA splicing, RNA polyadenylation and the subsequent export from the nucleus to the cytoplasm (21, 22). RBPs can also modify the RNA (23). Furthermore, RBPs control mRNA localization, translation and stability. For instance, the RBPs ZFP36L1 and ZFP36L2 induce quiescence in developing B cells to allow for efficient B cell receptor rearrangement (24). ZFP36L1 is also required for the maintenance of the marginal-zone B cell compartment (25). For germinal center B cells that undergo cell cycle progression and affinity maturation, the expression of the RBP PTBP1 is key (26). In thymocytes, ZFP36L1 and ZFP36L2 dampen the DNA-damage response, which promotes their differentiation into mature T cells (27). In the periphery, Roquin suppresses T helper cell differentiation (28, 29). Also m6A modifications are important for T helper cell differentiation, as evidenced in mice lacking the methyltransferase METTL3 in T cells (30).

Not only T cell differentiation, but also T cell effector function is tightly regulated by RBPs. Genetic ablation of the RBP Regnase-1 reprogrammed CD8 T cells into long-lived effector CD8 T cells, resulting in increased tumour control (31). In a patient, a nonsense-mutation in ROQUIN-1 resulted in hyperinflammation, including hypercytokinemia in T cells and monocytes (32). Another example is ZFP36L2, which blocks the cytokine production in memory CD8 T cells from pre-formed mRNA in the absence of activation signals, thereby preventing aberrant production of effector molecules (33).

Even though these examples clearly highlight the importance of RBPs in regulating gene expression in lymphocytes, studies have thus far only addressed the contribution of individual RBPs. The overall expression profile of RBPs in primary human B cells and T cells is not well-documented yet critical for our understanding of regulation of gene expression in lymphocytes.

In this study, we combined lists of previously experimentally defined and computationally predicted RBPs to generate a list of putative RBPs. As a proxy for RBP expression, we catalogued the mRNA and protein expression of these putative RBPs in primary human B cells and T cells. We observed clear differences of RBP expression levels between lymphocyte subsets. Furthermore, upon differentiation, the RBP expression profile significantly altered, which resulted in a shift of functional annotations of RBPs. Lastly, we identified an RBP signature that is specific for CD4+ T cells and CD8+ T cells with a high cytotoxic potential. In conclusion, RBP expression is lymphocyte-type specific and the RBP expression shows dynamic changes upon differentiation.

RESULTS

RNA-Binding Proteins Are Abundantly Expressed in Human B and T Lymphocytes

To investigate the overall mRNA and protein expression of RBPs in human lymphocytes, we first generated a comprehensive list of putative RBPs. We included RBPs that were identified by RNA-interactome capture on multiple cell lines including, HEK293, HeLa-S3, MCF7, MCF10A, U2OS and Jurkat cells (34–36). This list was supplemented with computationally predicted RBPs based on the presence of a defined list of RNA-binding domains (RBDs) (36, 37). This compiled list resulted in 3233 unique putative RBPs (from here on defined as ‘RBPs’) (Figure 1A and Supplementary Table 1).

To define the global RBP gene expression in human B and T lymphocytes, we compiled previously published RNA-sequencing (RNA-seq) data on human CD19+ B cell, CD4+ T cell and CD8+ T cell subsets that were isolated from the blood of 3-4 healthy human donors (38). On average, 12.5x10^6 reads per sample (range: 7.97x10^6–19.15x10^6 reads) could be mapped onto the human transcriptome. A total of 12,830 gene products (>0.1 TPM) were detected in all lymphocyte subsets combined. 2983 of the 3233 RBPs (92.3% of our reference list) were detected at the RNA level in human B and T lymphocytes (>0.1 TPM, Figure 1B and Supplementary Table 1), of which 2189 were identified in RNA-interactome capture studies and 794 were computationally predicted RBPs. The number of RBP transcripts in human B and T lymphocytes was similar to that of the epithelial cell line HeLa-S3 and the myelogenous leukemia cell line K562 cells, and overlapped for 90.1% [HeLa-S3: 2843 RBPs, K562: 2826 RBPs, Supplementary Figures 1A, B (39)].

To calculate the number of RBPs expressed at the protein level in B and T lymphocytes, we used previously published mass spectrometry (MS) data of B cell and T cell subsets of 4 donors (40) that were similarly prepared and selected as the ones in the RNA-seq dataset we used (38). In total, 9436 proteins were identified in all B cell and T cell subsets combined, of which 96.8% (9136 proteins) were also expressed at the RNA level (Supplementary Figure 1C). Overall, 2617 RBPs (80.9% of our
Reference list) were detected at the protein level (Figure 1B), and 2596 RBPs (80.2%) were detected at both RNA and protein level (Figure 1B). This high overlap corroborated with the overall high expression levels of RBPs (Figure 1C; p-value: 6.2e-12 for RNA and 2.1e-12 for protein). The top 20 expressed RBPs at RNA level included several ribosomal proteins (RPL3, RPL4, RPS3, RPS27), translation-related proteins (EEF1A1, EEF1G, EIF1) and splicing-related proteins (DDX5, SR5F5, HNRNPA1, HNRNPL) (Figure 1D). At the protein level, the top 20 expressed RBPs included the RNA stability-related protein [VIM (44)], the splicing-related protein HNRNPA2B1 (45), the ribosomal protein RPS27A, and the moonlighting RBPs ENO1 and GAPDH [Figure 1D (46, 47)].

We next determined which RNA-binding domains (RBDs) are present in the RBPs detected at the RNA level. Using previously reported RBDs [Supplementary Table 1 (36, 37)] and the protein families database [Pam (48)], we detected a broad range of RBDs. [Supplementary Table 1]. The top 20 RBDS included classical RBDs, such as the RNA-recognition motif (RRM; 5.8%, present in e.g. CELF2, CNOT4, ELAVL2, HNRNPL and PABPC1) and the DEAD helicase motif (DEAD; 2.1%, present in e.g. DDX1, DDX10, DHX16). We also found a variety of zinc-finger protein domains, including the zinc-finger C2H2 (zf-C2H2; 3.2%, present in e.g. ZNF638, ZMAT3), zinc-finger metazoans (zf-met; 1.1%, present in e.g. ZFR2, TUT1), zinc-finger CCCH (zf-CCCH; 1.0%, present in e.g. ZFP36L1, RBM27, ZC3H10), zinc-finger CCHC (zf-CCHC; 0.5%, present in e.g. ZCRB1, CPSF4) and the zinc-finger Ran binding protein (zf-RanBP; 0.5%, present in e.g. RBM5, RBM10) (Figure 1E). In addition, RBPs containing the top 20 RBDS were commonly identified using RNA-interactome capture studies [Supplementary Figure 1D]. This included RBPs containing the zf-C2H2 domain, a known DNA-binding domain that has recently also been identified as a RNA binding domain (49, 50). 52.8% of the RBPs contained non-canonical RNA-binding domains (1574 RBPs; Figure 1E), which were by and large present in experimentally identified RBPs [Supplementary Figure 1D]. These included ribosomal proteins (RPL18 and RPL5), the RNA processing molecule DUSP11, RNA splicing-related RBPs (AHNK, PCF11, SNIP1, SCAF11, SNRNP40) and the exoribonuclease EXOSC3. A similar distribution of the top 20 RBDS was present in RBPs detected in HeLa-S3 and K562 cells [Supplementary Figure 1E], indicating that the RBD distribution is not a specific feature of lymphocytes.

RBPS regulate many processes, which includes RNA splicing, stability, subcellular localization of RNA, RNA modification, and translation (51). Using protein annotations from the human protein atlas database (52), we found that 1178 RBPs (41.7%) were annotated as regulators of at least one of these five RNA-related processes [Figure 1F, left panel], of which 24% were
annotated for multiple RNA-related processes (Figure 1F, right panel). Combined, these data show that human lymphocytes express a wide variety of RBPs with a diverse set of RBDs.

**Human B Cells and T Cells Have a Distinct RBP Signature**

To determine whether and how RBP expression differed between B cells and T cells, we analyzed CD19+ B cells, CD4+ T cells, and CD8+ T cells separately in the RNA-seq and MS datasets employed in Figure 1. Overall, 2923 RBPs (97.0%) and 2551 RBPs (97.5%) were detected in all three subsets at the RNA and protein level, respectively (Supplementary Figures 2A, B and Supplementary Table 2). Only a few RBPs were detected in one specific cell type (Supplementary Figures 2A, B). B cells exclusively expressed members of the ribonuclease A superfamily (RNASE1, RNASE2 and RNASE3) and the RBP DAZL. The RBPs RBM24 and PABPC3 were only detected in CD4+ T cells, and NCBP1L2 and A1CF were specifically expressed in CD8+ T cells (Supplementary Table 2). At the protein level, 6 RBPs were specifically detected in CD19+ B cells, which included the ribonuclease RNASE7. The RBPs CPEB2, PAIB2B and TRMT44 were exclusively detected in CD4+ T cells, and the RBPs AICDA and HENMT1 were specifically detected in CD8+ T cells (Supplementary Table 2).

For the majority of RBPs detected in CD19+ B cells (85.1%, 2550 RBPs), CD4+ T cells (86.0%, 2571 RBPs) and CD8+ T cells (85.6%, 2560 RBPs) transcript and protein expression was co-detected (Supplementary Figure 2C). Only 425 RBPs, 386 RBPs and 400 RBPs, were only detected at the RNA level, and 22 RBPs, 31 RBPs and 32 RBPs at the protein level in CD19+ B cells, CD4+ T cells and CD8+ T cells, respectively (Supplementary Figure 2C and Supplementary Table 2). In line with the substantial overlap of RBPs co-detected at RNA and protein level, the correlation between the RNA and protein abundance for RBPs was high in CD19+ B cells (Pearson’s coefficient: 0.60), CD4- T cells (Pearson’s coefficient: 0.60) and CD8- T cells (0.61) compared to non-RBP genes (Pearson’s coefficients: 0.42-0.44, Supplementary Figure 2D).

We next questioned whether the global RBP expression differed between the three lymphocyte subsets. Principal Component Analysis (PCA) revealed that the RBP mRNA and protein expression alone separates B cells from T cells just as effectively as a PCA performed on all genes (Figure 2A and Supplementary Figure 2E). Differential expression (DE) analysis on all genes and protein, followed by filtering for RBPs, revealed clear differences between B cells and T cells. 695 and 644 DE RBPs (82.3% and 76.3% of the total DE RBPs) were found DE at the mRNA level between CD19+ B cells and CD4+ T cells, or CD8+ T cells, respectively (Figure 2B and Supplementary Table 2; LFC > 0.5; p-adjusted<0.01). CD4+ T cells and CD8+ T cells were more closely related, with only 68 DE RBPs (8.1% of all DE RBPs, Figure 2B and Supplementary Table 2). Of note, to prevent a bias towards DE genes with relatively low transcript abundance we utilized the lfcShrink function, which shrinks log2 fold change (LFC) values of genes with low counts [53], see Methods]. RBP protein expression showed similar trends, with 40 and 24 DE RBPs between CD19+ B cells and CD4+ T cells or CD8+ T cells, respectively, and only 6 DE RBPs between CD4+ T cells and CD8+ T cells (Supplementary Figure 2F and Supplementary Table 2; LFC > 0.5; p-adjusted<0.05). 84.4% of the DE RBPs at protein level were also DE RBPs at RNA level (Supplementary Figure 2G). Indeed, unsupervised clustering of the DE RBPs clearly distinguished B cell- from T cell-associated RBP clusters (Figures 2C, D).

To investigate the functional annotation of the DE RBPs, we focused on RBPs that were significantly higher expressed by either B cell or T cell populations (Figure 2E). We studied RBPs that are annotated regulators of RNA splicing, stability, subcellular localization of RNA, RNA modification, and translation, as defined by protein annotation from the human protein atlas database. Of note, although we focus on individual RNA processes, every known RNA-related function of each individual RBP was included in this analysis. We examined 107 (32.5%) of the B cell-associated RBPs and 49 (28.0%) of the T cell-associated RBPs (Figure 2F, left panel). The majority of these RBPs (B cell RBPs: 82.2%, T cell RBPs: 83.7%) were annotated for one function, and 17.8% and 16.3% for multiple functions for B cells and T cells, respectively (Figure 2F, middle panel). Interestingly, the relative distribution of RBPs annotated for these five RNA processes differed between B cells and T cells. Whereas 52.3% of RBPs in B cells were annotated for translation, this was only the case for 30.6% in T cells (Figure 2F, right panel). Conversely, only 17.8% was annotated for RNA splicing in B cells, but reached 30.6% in T cells (Figure 2F, right panel). In conclusion, the overt differential RBP expression between human B cells and T cells shown here possibly reflects a distinct distribution between different classes of RBPs.

**RBP Expression Changes Upon B Cell Differentiation**

Several B cell subsets can be found in the peripheral blood including naive B cells, memory B cells and plasmablasts (Figure 3A). Whereas plasmablasts produce vast quantities of antibodies and are short-lived, memory B cells are long-lived and for the most part quiescent (54). We found that the phenotypical differences between these three B cell subsets is echoed in their RBP expression profile. We identified 1308 DE RBPs at RNA level, and 96 DE RBPs at protein level between naive B cells, memory B cells and plasmablasts (Supplementary Figures 3A, B and Supplementary Table 3). 69.1% of the DE RBPs at protein level are detected also at the RNA level (Supplementary Figure 3C). In particular, although only 151 DE RBPs were found between naive and memory B cells, plasmablasts showed a distinct RBP profile, with 1185 and 891 DE RBPs between naive or memory B cells and plasmablasts, respectively (Supplementary Figure 3A and Supplementary Table 3). The top 20 DE RBPs at both the RNA and protein level spanned a wide range of abundance, and included RM2, APOBEC3B, METTL5 and LGALS3 (Figures 3B, C and Supplementary Table 3). Hierarchical clustering of DE RBPs at RNA level revealed three clusters between B cell subsets (Figure 3D and...
Supplementary Table 3. 188 RBPs were highly expressed in plasmablasts (cluster 1), 541 RBPs were highly expressed in memory B cells (cluster 2) and cluster 3 with 579 RBPs were highly expressed in naive and memory B cells, respectively (cluster 3). Hierarchical clustering on protein levels revealed similar differential RBP expression patterns (Figure 3E). Within these three clusters of DE RBPs at the RNA level, we isolated RBPs annotated for RNA splicing, stability, subcellular localization of RNA, RNA modification, and translation. This included 67 (35.6%) RBPs in cluster 1, 204 (44.4%) RBPs in cluster 2, and 214 (37%) RBPs in cluster 3 (Figure 3F, left panel). Again, 75-78% of the RBPs was annotated for one function (Figure 3F, middle panel), and the prime annotation of RBPs was translation in all three clusters (Figure 3F, right panel). Interestingly, whereas RBPs annotated for RNA splicing were also abundant in naive and memory B cell subsets with 31.3% and 40.2%, respectively, plasmablasts (cluster 1) contained only 6.0% RBPs annotated for RNA splicing (Figure 3F, right panel). Instead, 44.8% of RBPs expressed in plasmablasts annotated for RNA transport (Figure 3F, right panel). STRING-analysis on splicing-related RBPs from cluster 3 (naive-memory B cells) revealed networks consisting of known splicing factors, such as the SR protein family members SRSF1, SRSF4, SRSF3, SRSF6, in addition to NUDT21 and HNRNPLL (Figure 3G). For transport-annotated RBPs from cluster 1 (plasmablast), the interaction networks included the RBP SLBP, which regulates mRNA export (55), and the RBP TST, which regulates the transport of ribosomal RNA [Figure 3H (56)].

Gene Ontology (GO) analysis on the DE RBPs identified in cluster 2 and 3 showed a shared enrichment of GO-terms associated with various RNA-related processes, including RNA splicing, translation and RNA processing, while cluster 1 showed enrichment of the GO-term associated with translation (Supplementary Figure 3D and Supplementary Table 7).
Cluster 3 displayed a moderate enrichment for GO-terms related to RNA stability (3’-UTR-mediated mRNA, mRNA destabilization) and regulation of RNA splicing (mRNA splice site selection, positive regulation of RNA splicing, negative regulation of RNA splicing; Supplementary Figure 3D and Supplementary Table 7). In conclusion, the RBP expression differs between B cell subsets, and involves different types of post-transcriptional regulatory functions.
RBP Expression Changes Upon CD4^+ T Cell Differentiation

Naive T cells (Tnaive) undergo differentiation into effector T cells, which are rarely found in the peripheral blood of healthy donors (57). Rather, central memory (Tcm) and effector memory (Tem) CD4^+ T cell subsets, which develop during the course of infections, are present in the blood and differentially contribute to recall responses upon recurring infections [Figure 4A (58)]. Similar to B cells, we find RBPs differentially expressed in the CD4^+ T cell subsets Tnaive, Tcm and Tem at RNA (n=774), and

![Diagram](image1)

**FIGURE 4** | RBP expression alters upon CD4^+ T cell differentiation. (A) Diagram depicting the analysed CD4^+ T cell subsets. (B, C) Expression levels of RBPs detected at RNA (B) or protein level (C) in human CD4^+ T cells ranked according to expression levels. Red dots indicate top 20 most differentially expressed RBPs based on Log2 Fold Change. (D, E) Unsupervised clustering of DE RBPs at RNA (D) or at protein level (E) between naive (Tnaive), central memory (Tcm) and effector memory (Tem) CD4^+ T cells depicted in a heatmap. RNA: n=5 donors, protein: n=4 donors. (F) Left panels: RBPs annotated for RNA splicing, stability, subcellular localization of RNA, RNA modification, and translation (dark colors) or for other processes (light colors) in the three clusters defined in (D). Middle panels: relative distribution between the 5 indicated RBP classes. Right panels: Percentage of RBPs annotated for indicated RNA-related biological processes. (G, H) String analysis on translation-related RBPs (G) identified in cluster 3 and on RNA transport-associated RBPs (H) identified in cluster 2. TPM, Transcripts per kilobase per million; CN, Protein copy number.
at protein level (n=115; Supplementary Figures 4A, B and Supplementary Table 4). 48% of the DE RBPs at protein level are detected also at the RNA level (Supplementary Figure 4C). The top 20 DE RBPs included RBPs such as, APOBEC3H and PAPBC3 (RNA level) and OASL and ANXA2 (protein level, Figures 4B, C and Supplementary Table 4).

Hierarchical clustering of the DE RBPs revealed three clusters (Figures 4D, E), with cluster 1 (Tnaive) containing 145 RBPs, cluster 2 (Tem) containing 366 RBPs, and cluster 3 (Tcm) containing 263 RBPs (Supplementary Table 4). This differential expression of RBPs was also apparent at the protein level (Figure 4E, 115 DE RBPs, Supplementary Table 4). To gain more insights into the biological processes of the RBPs in the different clusters, we performed Gene Ontology (GO) analysis (Supplementary Table 7). Whereas metabolic processes were enriched in all three clusters, cluster 2 and 3 were enriched for GO-terms associated with translation (translation initiation, cytoplasmic translation) and with RNA transport (Supplementary Figure 4D and Supplementary Table 7). Cluster 2 also showed a moderate enrichment for RBPs associated with regulation of RNA stability (RNA destabilization, 3'-UTR-mediated mRNA destabilization; Supplementary Figure 4D and Supplementary Table 7).

When we specifically isolated RBPs annotated for RNA splicing, stability, subcellular localization of RNA, RNA modification, and translation, we found that 103 (39.2%) RBPs of the DE RBPs belong to these 5 RBP classes in cluster 1, 148 RBPs in cluster 2 (40.4%) and 84 RBPs in cluster 3 (57.9%) (Figure 4F, left panels). Only a fraction of RBPs is associated with more than one of these functions (cluster 1: 17.5%, cluster 2: 26.4%, cluster 3: 25%; Figure 4F, middle panel). When CD4+ T cells differentiate, the relative distribution of functional RBP annotation alters. 83.3% of the RBPs associated with the 5 RBP classes were linked to translation in cluster 3 (Tcm), compared to 51.5% and 43.2% in cluster 1 (Tnaive) and cluster 2 (Tem), respectively (Figure 4F, right panels). Conversely, in cluster 2 (Tem), the percentage of RBPs annotated for RNA transport are with 41.2% primarily found in cluster 2 and much less so in cluster 2 and 3 with 15.5% and 13.1%, respectively (Figure 4F, right panels). STRING-analysis on the transport-related RBPs of cluster 3 revealed an enrichment of 53 ribosomal proteins and of other translation-associated RBPs, such as PABPC1, YBX1 and FAU (Figure 4G). The RNA-transport-related RBPs of cluster 2 included the mRNA export-associated RBPs DDX19B, SARNP, MAGOH and THOC2 (Figure 4H). Combined, our findings reveal that the RBP expression landscape changes throughout CD4+ T cell differentiation, which results in a relative enrichment of specific RBP classes in different CD4+ T cell subsets.

**RBP Expression Changes Upon CD8+ T Cell Differentiation**

We then focused on the CD8+ T cell differentiation subsets. Our dataset also included effector CD8+ T cells (Teff), which was included in the analysis, in addition to Tnaive, Tcm and Tem CD8+ T cell subsets (Figure 5A). 707 RBPs were differentially expressed at the RNA level between Tnaive, Tcm and Tem and Teff, and 115 RBPs at the protein level (Supplementary Figures 5A, B and Supplementary Table 5). 44.1% of DE RBPs at protein level were also detected at the RNA level (Supplementary Figure 5C). The top 20 DE RBPs included RBPs like JAKMIP1 and OASL (RNA level) and EIF4EBP3 and FLNB (protein level, Figures 5B, C and Supplementary Table 5). Hierarchical clustering of RBP expression resulted 3 clusters (Figure 5D). Cluster 1 contained 297 RBPs highly expressed in Tem and Teff CD8+ T cells (Figure 5B and Supplementary Table 5). Cluster 2 (176 RBPs) also included Tem an Teff CD8+ cells, and to a lesser extent in Tcm cells. Cluster 3 (234 RBPs) included primarily Tnaive cells, but also Tcm cells (Figure 5B and Supplementary Table 5). Similar clusters were identified at RBP protein level (Figure 5E, 177 DE RBPs, Supplementary Table 5).

In CD8+ T cell subsets, 67 RBPs in cluster 1 (38.1%), 84 RBPs in cluster 2 (35.9%), and 143 RBPs in cluster 3 (48.1%) were annotated as regulators of RNA splicing, stability, subcellular localization of RNA, RNA modification, or translation (Figure 5F, left panels), with a minority of RBPs (20-28%) linked to multiple functions (Figure 5F, middle panels). We found that cluster 3 was relatively enriched for translation-associated RBPs (71.3%), compared to cluster 1 and cluster 2 with 34.5% and 44.8%, respectively (Figure 5F, right panels). Conversely, cluster 1 and 2 were enriched for RBPs associated with RNA transport (cluster 1: 43.3%, cluster 2: 46.4%), and this RBP class was 12.6% only minor in cluster 3 (Figure 5F, right panels). STRING-analysis on translation-associated RBPs from cluster 3 revealed the interaction network between 56 ribosomal proteins and 10 eukaryotic translation initiation factors (Figure 5G). The RNA-transport associated RBPs in cluster 2 and 3 included RBPs involved in RNA export (THOCS (59) and SARNP (60), Figure 5H).

Gene Ontology (GO) analysis on the DE RBPs also showed in cluster 3 - in addition to catabolic processes - an enrichment of GO-terms associated with translation, i.e. cytoplasmic translation, translation initiation and positive regulation of translation (Supplementary Figure 5D and Supplementary Table 7). Cluster 1 displayed a moderate enrichment for GO-terms related to RNA stability (3'-UTR-mediated mRNA destabilization, regulation of mRNA stability, Supplementary Figure 5D and Supplementary Table 7). In conclusion, CD8+ T cells change their RBP expression landscape throughout differentiation, with specific RBP classes enriched in different CD8+ T cell subsets.

**Specific RBP Expression Associates With T Cell Cytotoxicity**

T cells can acquire cytotoxic function when they differentiate into effector cells. Importantly, whereas CD8+ T cells are generally classified as cytotoxic, not all CD8+ T cells display cytotoxic features (61–63). Conversely, a subset of human CD4+ T cells also shows cytolytic features (64–66). We therefore sought to identify RBPs that were associated with a high cytotoxic capacity in human CD8+ T cells and CD4+ T cells. As source of T cells, we used previously published single-cell RNA-seq (scRNA-seq) data on blood-derived human CD8+ and CD4+ T cells (67–69).
Because only memory and effector T cells can be cytotoxic, we excluded naive T cells from our analysis based on their high gene expression of CCR7, LEF1 and SELL (Supplementary Figures 6A–D). We then identified and integrated the expression of 8 cytotoxic genes (9) i.e. FGFBP2, GZMB, GZMH, PRF1, NKG7, CX3CR1, GNLY and ADGRG1 into a cytotoxic score (see Methods; Figure 6A and Supplementary Figures 6E, F). Dimensional reduction analysis revealed that CD8$^+$ and CD4$^+$ T cells with a low (bottom 10%) or high cytotoxic score (top 10%) form two distinct clusters.
High expression of ITGB1 in CD8+ and CD4+ T cells with a high cytotoxic score confirmed the selection for cytotoxic T cells \cite{61, 64, Figures 6D, E}. In addition, 16 RBPs were significantly upregulated in CD8+ T cells with a low cytotoxic score, whereas 36 RBPs were preferentially expressed in CD8+ T cells with a high cytotoxic score (Figure 6D and Supplementary Table 6; LFC>0.5; P-adjusted<0.01). Likewise, 87 RBPs and 41 RBPs were upregulated in CD4+ T cells with a low and with a high cytotoxic score, respectively (Figure 6E and Supplementary Table 6).

Intriguingly, the differential RBP expression between CD8+ and CD4+ T cells with a low or high cytotoxic score was strikingly similar (Figure 6F). 13 RBPs were upregulated in CD8+ and CD4+ T cells with a low cytotoxic score (Figure 6F), which included 8 ribosomal proteins, e.g. RPL13A, RPL10 and RPL4 which are accessory to the translation regulation \cite{70}, and the translation initiation factor EEF1G (Figures 6G, H). 25 RBPs that were upregulated in both CD8+ and CD4+ T cells with a high cytotoxic score (Figure 6F) included cytidine deaminases APOBEC3G and APOBEC3C,
to determine whether the difference in RNA abundance is also echoed at the protein level.

Also, cytotoxic T cells display a unique RBP expression profile. Compared to non-cytotoxic T cells, cytotoxic T cells express lower mRNA levels of several ribosomal proteins. Whether the differences at the mRNA level for ribosomal proteins is also reflected at the protein level is still unknown. In addition, whether some of these ribosomal proteins display any transcript specificity, as was shown for RPL10A and RPS25 (70), remains to be defined. Interestingly, a T-cell specific loss of Rps26 did not affect overall translation rates, but rather increased p53 signalling, and thus resulted in cell death (84). A significant increase of p53 expression was also observed in HeLa cells upon knock down of 24 out of 80 ribosomal proteins and has been attributed to the accumulation of free ribosomal proteins in the nucleus (85, 86). This decreased viability will thus impede the study of at least a subset of ribosomal proteins in T cells.

Cytotoxic T cells also exhibited an increased expression of the mRNA cytidine deaminases APOBEC3C and APOBEC3G. Previous studies reported that APOBEC expression increases upon T cell activation (87), which was primarily associated with viral restriction (88). It is also conceivable that increased APOBEC expression is involved in regulating the fate of endogenous mRNAs in cytotoxic T cells. Interestingly, the specific RBP profile linked to cytotoxicity is shared by CD4+ T cells and CD8+ T cells, a feature which may point to a similar differentiation program towards cytotoxicity.

RNA-binding proteins are critical mediators in shaping lymphocyte differentiation and effector function (24-28, 30–33). The RBP expression catalogue we provide here should help to further dissect the role of RBPs in B cell and T cell differentiation and function. It is important to note that this RBP catalogue primarily serves as a resource, and thus as a starting point for uncovering the RBP-mediated regulation in lymphocyte differentiation. Indeed, whether alterations in the RBP signature during lymphocyte differentiation are the cause or consequence of differentiation is yet to be determined. Furthermore, RBP expression by itself cannot be interpreted as direct interaction of RBPs with RNA. In fact, RNA interactome capture in cell-cycle arrested U2OS cells revealed that increases in protein abundance of some RBPs did not result in increased RNA binding (89). In addition, the regulation of RBPs is highly context-dependent and is most likely variable between cell types (90). The recent development of novel RNA interactome capture methodologies will be instrumental in identifying the RBPs that truly interact with RNA in human lymphocytes (89, 91, 92).

RBP interactions with RNAs can be highly versatile and are subject to rapid changes upon extrinsic signals. For instance, the RBP ZFP36L2 is expressed to a similar extent in memory T cells and re-activated T cells, yet only blocks translation in resting memory T cells (33). Similarly, a large fraction of ribosomal proteins does not interact with ribosomal RNA. The mode of action of these non-ribosomal RNA binding ribosomal proteins (RBPs) is to date enigmatic and requires further investigation. Lastly, in addition to classical RBPs, recent studies have revealed the presence of enigmatic RBPs, which are primarily annotated
for other cellular, non-RNA binding related functions. This is exemplified by metabolic enzymes from the tricarboxylic acid (TCA) cycle (93–95). Their relative contribution to RNA regulation during lymphocyte differentiation and effector function is yet to be experimentally confirmed. Nonetheless, the role of RBPs in genetic diseases is becoming appreciated (96), and defining the RBP expression presented in the study presented here may contribute to deciphering dysregulated RBP expression and function also in immune-related diseases.

**MATERIAL AND METHODS**

**Data Sets**

Raw RNA-sequencing (RNA-seq) data were retrieved from the gene expression omnibus repository (GEO, NCBI) or from the European Nucleotide Archive (ENA). Data from CD19+ B cells and from CD4+ T cell differentiation subsets (n=4 donors with 4 B cell populations each), from CD4+ T cells (n=3-4 donors with 7-8 CD4+ T cell populations each) and CD8+ T cells and respective differentiation subsets (n=4 donors with 4 CD8+ T cell populations each) were retrieved from Monaco et al. [(38); accession number: GSE107011]. RNA-sequencing libraries from Monaco et al. (38) were composed of poly(A) enriched RNA. RNA-seq data of CD4+ T cell subsets (n=5 donors with 3 CD4+ T cell populations each) were retrieved from Ranzani et al. [(97); PRJEB4568]. RNA-sequencing libraries from Ranzani et al. (97) consisted of poly(A) enriched RNA. RNA-seq data of HeLa-S3 cells and K562 cells were obtained from Martinez et al. [39]; GSE126218 and were comprised of RNA-sequencing libraries composed of poly(A) enriched RNA. Quantitative mass spectrometry (MS) data, consisting of imputed label-free quantification (LFQ) and protein copy numbers (CN), were retrieved from Rieckmann et al. (40) and encompassed CD19+ B cells, CD4+ and CD8+ T cells and their respective differentiation subsets (n=4 donors). Data sets were selected based on using near identical markers for selecting lymphocyte subsets: Lymphocyte subsets in the RNA-seq and MS data sets were prepared as follows: CD19+ B cells: naive (RNA-seq: CD27 IgD-, MS: CD27 Mitotracker), memory (RNA-seq: CD27 IgD-, MS: CD27 Mitotracker) and plasmablasts (RNA-seq: CD27 IgD-, MS: CD27 Mitotracker) and respectively CD4+ T cells: naive (RNA-seq: CCR7 CD45RA CD45RO, MS: CCR7 CD45RA), memory (RNA-seq: CCR7 CD45RA CD45RO, MS: CCR7 CD45RA), and effector memory (RNA-seq: CCR7 CD45RA CD45RO, MS: CCR7 CD45RA); CD8+ T cells: naive (CCR7 CD45RA), memory (CCR7 CD45RA, MS: CCR7 CD45RA), and effector memory (CCR7 CD45RA) and effector CD8+ T cells (CCR7 CD45RA).

Single-cell RNA-sequencing (scRNA-seq) data of blood-derived CD4+ and CD8+ T cells were retrieved from the GEO repository: Zheng et al. (69); GSE98638, Guo et al. (67); GSE99254, Zhang et al. (68); GSE108989.

**RBP Reference List**

The list of annotated human RNA-binding proteins (RBPs) was created by aggregating published data of RNA interaction capture assays that were performed on HEK293, HeLa, MCF7, MCF10A, U2OS and Jurkat cells (34–36), which resulted in a list of 2356 RBPs. This list was supplemented with 977 computationally identified RBPs from Gerstberger et al. (37), and the EuRBP-DB (36), http://eurpdb.syshospital.org/, accessed on 19-11-2019. This RBP list with 3333 proteins was manually curated to exclude histones (18 histones), possible contaminants (ITGA1 and ITGBI), and mitochondrial RBPs (80 RBPs), resulting in a list of 3233 RBPs.

**RNA-Sequencing Analysis**

RNA-sequencing reads were quasi-mapped using Salmon [version 1.0 (98)] onto the human coding transcriptome GRCh38 from Gencode (v36, May 2020). Of the CD4+ T cell, CD8+ T cell and CD19+ B cell samples retrieved from Monaco et al. (38), an average of 12.5 x 10^6 reads was quasi-mapped onto the human coding transcriptome. For the CD4+ T cell differentiation samples, retrieved from Ranzani et al. (97), an average of 11.4 x 10^6 reads was quasi-mapped onto the human coding transcriptome. Transcript-level estimates were imported and summarized to the gene-level by using the tximport function [tximport package, version 1.16.1 (99)]. To define the overall expression of RBPs subsets were grouped together as indicated. Differential gene expression analysis was performed on all detected genes using DESeq2 [version 1.28.1 (53)]. P-value was adjusted using the Bejamini-Hochberg procedure. Log2 fold change values were adjusted using the lfcShrink function, which is part of the DESeq2 package. Genes were considered differentially expressed with an absolute log2 fold change (LFC) >0.5 and a p-adjusted <0.01. RBPs that were differentially expressed were filtered from the list of differentially expressed genes. For differential gene expression analysis of total B cells, CD4+, and CD8+ T cell populations, we averaged the RNA-seq counts of differentiation subsets per donor. TPM (transcript per kilobase per million) counts were calculated by Salmon and used for plotting. Of note, TPM counts are corrected for library depth, library size, and transcript length, and thereby allow a fair comparison between populations. The number of detected RBPs per cell type, and the RBP expression rank were based on averaged TPM per cell type. Top 20 differentially expressed proteins were identified based on the log2 fold change values.

**Single Cell RNA-Seq Data Analysis**

ScRNA-seq datasets were analysed using Seurat [version 4.0.1 (100)]. Count matrices of (67–69) were filtered for “PTC”, corresponding to peripheral blood-derived CD8+ T cells (CD3+CD8+). To identify conventional blood-derived CD4+ T cells, count matrices of references (67–69) were filtered for “PTC” (CD3+CD4+CD25) and “PTY” (CD3+CD4+CD25). To correct for dataset specific effects from the three individual scRNA-seq datasets, we employed a published scRNA-seq data integration method (101). The inter-individual donor batch-effect was corrected using the `vars.to.regress` argument in SCTransform (Seurat v4). Unsupervised clustering was performed on Uniform Manifold Approximation and Project (UMAP) dimensional reduction using the top 30 principal components (PCs). Cells expressing high levels of naïve T cell associated genes like CCR7, LEF1 and SEL2 (102, 103) were
excluded from downstream analysis. Differential gene expression analysis was performed using the Model-based Analysis of Single-cell Transcriptomics (MAST) test (104). Genes were considered differentially expressed based on a p-adjusted < 0.05 and an absolute log2 fold change > 0.5.

**Cytotoxic Score Calculation**

The cytotoxic score of CD4+ T cells and CD8+ T cells was obtained from the scRNA-seq data by selecting for the top 7 most correlated (Pearson’s correlation) genes with FGFBP2 expression (9). (Supplementary Figures 6A, B). To obtain the cytotoxic score for each cell, a Z-score of expression for each of the 8 cytotoxic genes (FGFBP2, GZMB, GZMH, PRF1, NKG7, CX3CR1, GNLY and ADGRG1) was calculated for the whole dataset. Z-scores from all 8 genes were averaged per cell and served as the cytotoxic score. Cells with high (top 10%), intermediate (10-90%) or low (bottom 10%) cytotoxic score were selected and used for analysis.

**Mass Spectrometry Analysis**

Differential protein expression analysis was performed with Differential Enrichment analysis of Proteomics data (DEP) [version 1.12.0 (105)] using the imputed LFQ values. LFQ values of all detected proteins were used for differential protein expression analysis. Proteins were considered differentially expressed with a p-adjusted value < 0.05 and an absolute log2 fold change > 0.5. RBPs that were differentially expressed were filtered from the list of differentially expressed proteins. Protein abundance was presented in CN values and were filtered for expression levels (CN > 1). The number of RBPs detected among the different cell types was based on averaged CN values across cell types obtained from 4 donors. RBP rankings according to protein abundance was performed by using averaged CN values per cell type. The top 20 differentially expressed proteins were identified based on the log2 fold change values.

**RBD Annotation**

RNA-binding domain names were obtained from Gerstberger et al. (2014) and Liao et al. (2020). The existence of each RNA-binding domain was verified and updated based on information present in the protein families database [Pfam (48)] (Supplementary Table 1). Proteins containing RNA-binding domains were obtained from the PFAM database. When RBPs contained more than one RBD, each RBD was counted and included in the analysis. Human Protein Atlas annotations [HPA, https://www.proteinatlas.org on 28-03-2021 (52)] were used to classify proteins associated with RNA modification (keywords: "RNA AND Modification"), RNA splicing (keywords: "Spliceosome"), RNA stability (keywords: "RNA AND Stability"), RNA transport (keywords: "RNA AND Transport"), and Translation (keywords: "Translation"). Protein-protein association networks were generated using the STRING database [https://string-db.org/ (106)]. Gene ontology analysis was performed with the Panther database [version 16.0 (107)] on differentially expressed RBPs. A statistical overrepresentation test (Fisher’s exact with FDR multiple test correction) was performed with a reference list composed of all Homo Sapiens genes in the database. Overrepresented GO terms (FDR<0.05) were filtered for RNA-related functions. Full lists of overrepresented GO terms are provided in Supplementary Table 7.

**Plots and Graphs**

Plots and graphs were generated using ggplot2 [version 3.3 (108)]. Principal components analysis was performed using the plotPCA function from DESeq2 (53). Heatmaps were generated using the Heatmap package [version 1.0.12 (109)] in R (version 4.0.3). Venn diagrams were generated using the Venn tool from the University of Gent (accessed at http://bioinformatics.psb.ugent.be/webtools/Venn/).

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found here: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107011 Gene Expression Omnibus GSE107011 https://www.ebi.ac.uk/ena/browser/view/PRJEB5468 European Nucleotide Archive PRJEB5468 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125218 Gene Expression Omnibus GSE125218 https://www.nature.com/articles/ni.3693 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98638 Gene Expression Omnibus GSE98638 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99254 Gene Expression Omnibus GSE99254 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108989 Gene Expression Omnibus GSE108989.

**AUTHOR CONTRIBUTIONS**

NZ analyzed the data. BN provided technical and intellectual input on the data analysis. MW directed the study. NZ, BN, and MW wrote the manuscript. BN and MW conceptualized the study. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the ERC consolidator grant PRINTERS (817533) and the Oncode Institute.

**ACKNOWLEDGMENTS**

The authors would like to thank Drs. B. Popovic and I. Foskolou for critical reading of the manuscript.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.717324/full#supplementary-material
REFERENCES

1. Casanova JL, Abel L. Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories. *Annu Rev Pathol Mech Dis* (2021) 16:23–50. doi: 10.1146/annurev-pa0019-101429

2. Dunn GP, Old LJ, Schreiber RD. The Immunobiology of Cancer Immunosurveillance and Immunoediting. *Immunity* (2004) 21:137–48. doi: 10.1016/j.immuni.2004.07.017

3. Chemin K, Gerstner C, Malmström V. Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis. *Front Immunol* (2019) 10:353. doi: 10.3389/fimmu.2019.00353

4. Das D, Akhtar S, Kurra S, Gupta S, Sharma A. Emerging Role of Immune Cell Network in Autoimmune Skin Disorders: An Update on Pemphigus, Vitiligo and Psoriasis. *Cytokine Growth Factor Rev* (2019) 45:35–44. doi: 10.1016/j.cytogfr.2019.01.001

5. Killestein J, Eikelenboom MJ, Iezouz T, Kalkers NF, Adéř HJ, Barkhof F, et al. Cyto kinase Producing CD8+ T Cells Are Correlated to MRI Features of Tissue Destruction in MS. *J Neuroimmunol* (2003) 124:141–8. doi: 10.1016/S0165-5728(03)00265-0

6. Arbuckle MR, McLain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA. Development of Auto-Antibodies Before the Clinical Onset of Systemic Lupus Erythematosus. *Rev Med Interne* (2004) 25:175–6. doi: 10.1016/j.remi.2003.10.007

7. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies Against Type I IFNs in Patients With Life-Threatening COVID-19. *Sci (80 )* (2020) 370. doi: 10.1126/science.abd4585

8. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine Elevation in Severe and Critical COVID-19: A Rapid Systematic Review, Meta-Analysis, and Comparison With Other Inflammatory Syndromes. *Lancet Respir Med* (2020) 8:1233–44. doi: 10.1016/S2213-2600 (20)30404-5

9. Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, et al. Dysfunctional CD8+ T Cells Form a Proliferative, Dynamically Regulated Compartment Within Human Melanoma. *Cell* (2019) 176:775–89.e18. doi: 10.1016/j.cell.2018.11.043

10. Fenwick C, Joo Y, Jacquier P, Noto A, Banga R, Perreau M, et al. Roquin Suppresses the PI3K-mTOR Signaling Pathway to Inhibit T Helper Cell Differentiation and Conversion of Treg to T Fr Cells. *Immunity* (2017) 47:1067–82.e12. doi: 10.1016/j.immuni.2017.11.008

11. Cui X, Mino T, Yoshinaga M, Nakatsu A, Hia F, Yamasoba D, et al. Regnase-1 and Roquin Nonredundantly Regulate Th1 Differentiation Causing Cardiac Inflammation and Fibrosis. *J Immunol* (2017) 199:4066–77. doi: 10.4049/jimmunol.1701211

12. Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, et al. M6A mRNA Methylation Controls T Cell Homeostasis by Targeting the IL-7/STAT5/SOCS Pathways. *Nature* (2017) 548:338–42. doi: 10.1038/nature22349

13. Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, et al. Targeting REGNASE-1 Programs Long-Lived Effector T Cells for Cancer Therapy. *Nature* (2019) 576:471–6. doi: 10.1038/s41586-019-1821-z

14. Tavner SJ, Athanasopoulos V, Verloo P, Behrens G, Staal J, Bogaert DJ, et al. A Human Immune Dysregulation Syndrome Characterized by Severe Hyperinflammation With a Homozygous Nonsense Roquin-1 Mutation. *Nat Commun* (2019) 10:4779. doi: 10.1038/s41467-019-12704-6

15. Salerno F, Engels S, van den Biggelaar M, van Alphen FPJ, Guislain A, Zhao W, et al. Translational Repression of Pre-Formed Cytokine-Encoding mRNAs Prevents Chronic Activation of Memory T Cells. *Nat Immunol* (2018) 19:828–37. doi: 10.1038/s41590-018-0155-6

16. Castello A, Fischer B, Frese CK, Horos R, Alleaume AM, Foehr S, et al. Comprehensive Identification of RNA-Binding Domains in Human Cells. *Mol Cell* (2016) 63:696–710. doi: 10.1016/j.molcel.2016.06.029

17. Perez-Perrin JJ, Rogell B, Schwarz T, Stein F, Zhou Y, Rettel M, et al. Discovery of RNA-Binding Proteins and Characterization of Their Dynamic Responses by Enhanced RNA Interactome Capture. *Nat Commun* (2018) 9:4408. doi: 10.1038/s41467-018-06557-8

18. Liao JY, Yang B, Zhang YC, Wang XJ, Ye Y, Peng JW, et al. EuRBPDB: A Comprehensive Resource for Annotation, Functional and Oncological Investigation of Eukaryotic RNA Binding Proteins (RBPs). *Nucleic Acids Res* (2020) 48:D307–13. doi: 10.1093/nar/gkbz820

19. Gerstberger S, Hafner M, Tuschi T. A Census of Human RNA-Binding Proteins. *Nat Rev Genet* (2014) 15:829–45. doi: 10.1038/nrg3813

20. Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carre C, et al. RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types. *Cell Rep* (2019) 26:1627–40.e7. doi: 10.1016/j.celrep.2019.01.041

21. Martinez TF, Chu Q, Donaldson C, Tan D, Shokhirev MN, Saghatelian A. Accurate Annotation of Human-Coding Small Open Reading Frames. *Nat Chem Biol* (2020) 16:458–68. doi: 10.1016/j.nclbi.2019.0425-0
40. Rieckmann JC, Geiger R, Hornburg D, Wolf T, Kveler K, Jarrossay D, et al. Social Network Architecture of Human Immune Cells Unveiled by Quantitative Proteomics. *Nat Immunol* (2017) 18:583–93. doi: 10.1038/ni.3989

41. LeGrand JMD, Chan AL, La HM, Rossello FL, Anko ML, Fuller-Pace FV, et al. DiDX5 Plays Essential Transcriptional and Post-Transcriptional Roles in the Maintenance and Function of Spermatogonia. *Nat Commun* (2019) 10:2278. doi: 10.1038/s41467-019-09972-7

42. Diamond RH, Du K, Lee VM, Mohn KL, Haber BA, Tewari DS, et al. Novel Delayed-Early and Highly Insulin-Induced Growth Response Genes. Identification of HRS, a Potential Regulator of Alternative pre-mRNA Splicing. *J Biol Chem* (1993) 268:15185–92. doi: 10.1016/0021-9258(98)92415-3

43. Chang CH, Curtis JD, Maggi LB, Faubert B, Villarino AV, O'Hare PA, et al. Quantitative Proteomics. Social Network Architecture of Human Immune Cells Unveiled by Single-Cell Sequencing Data of Individual T Cells From Treatment-Naive Colorectal Cancer Patients. *Sci Data* (2019) 6:131. doi: 10.1038/s41597-019-0131-5

44. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-Based Map of the Human Proteome. *Cell* (2015) 162:1299–308. doi: 10.1016/j.cell.2015.08.011

45. Mayeda A, Krainer AR. Regulation of Alternative pre-mRNA Splicing. *Nat Rev Genet* (2013) 14:285–94. doi: 10.1038/nrg3461

46. Diamond RH, Du K, Lee VM, Mohn KL, Haber BA, Tewari DS, et al. Novel Delayed-Early and Highly Insulin-Induced Growth Response Genes. Identification of HRS, a Potential Regulator of Alternative pre-mRNA Splicing. *J Biol Chem* (1993) 268:15185–92. doi: 10.1016/0021-9258(98)92415-3

47. Chang CH, Curtis JD, Maggi LB, Faubert B, Villarino AV, O’Sullivan D, et al. Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis. *Cell* (2013) 153:1239. doi: 10.1016/j.cell.2013.05.016

48. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR, et al. Pfam: The Protein Families Database. *Nucleic Acids Res* (2014) 42:2222–30. doi: 10.1093/nar/gkt1223

49. Lu D, Searles MA, Klag A. Crystal Structure of a Zinc-Finger-RNA Complex Reveals Two Modes of Molecular Recognition. *Nature* (2003) 426:96–100. doi: 10.1038/nature02088

50. Hall TMT. Multiple Modes of RNA Recognition by Zinc Finger Proteins. *Curr Opin Struct Biol* (2005) 15:367–73. doi: 10.1016/j.sbi.2005.04.004

51. Diaz-Muñoz MD, Turner M. Uncovering the Role of RNA-Binding Proteins in Gene Expression in the Immune System. *Front Immunol* (2018) 9:1094. doi: 10.3389/fimmu.2018.01094

52. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2. *Genome Biol* (2015) 16:1. doi: 10.1186/s12859-014-0550-8

53. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The Generation of Antibody-Secreting Plasma Cells. *Nat Rev Immunol* (2015) 15:160–71. doi: 10.1038/nri3795

54. Pechman ET, Alperin E, Fiehn O, Wolfe RR, Turetsky MJ, Kasprzyk A. Mammalian Metabolism: A Cell-Based Approach. *Nature* (2015) 525:231–6. doi: 10.1038/nature14966

55. Silver MD, Wolfson SH, Brunetti PA, Alcorn SH, Wilbert AR, et al. Tissue-Antigen Specificity of Human B Cells Revealed by Proteomic Analysis of Plasma Cells. *Nat Immunol* (2018) 19:1007–15. doi: 10.1038/s41591-018-0045-3

56. Myers DR, Norlin E, Vercoulen Y, Roose JP. Active Tonic Mtorc1 Signals by CD8+ T Cells Mediate Protective Immunity Against Human Cancer. *J Immunother Cancer* (2020) RA581–1. doi: 10.1136/jitc-2020-sitc2020.0545

57. Zhong Y, Liao J, Zheng L, Zheng C, Song J, Zhang Q, et al. Global Characterization of T Cells in Non-Small-Cell Lung Cancer by Single-Cell RNA Sequencing. *Nat Med* (2018) 24:2678–85. doi: 10.1038/s41591-018-0045-3

58. Zheng Y, Zheng L, Zhang L, Hu X, Ren X, Zhang Z. Deep Single-Cell RNA Sequencing Data of Individual T Cells From Treatment-Naive Colorectal Cancer Patients. *Sci Data* (2019) 6:131. doi: 10.1038/s41597-019-0131-5

59. Wu J, Wu X, Ge Y, Chen H, Wu Y, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. *Cell* (2017) 169:1342–56.e16. doi: 10.1016/j.cell.2017.05.035

60. Cachot A, Bilous M, Liu Y-C, Li X, Rockinger A, Saillard M, et al. Tumor-Specific Cytolytic CD4+ T Cells Mediate Protective Immunity Against Human Cancer. *J Immunother Cancer* (2020) RA581–1. doi: 10.1136/jitc-2020-sitc2020.0545

61. Nicolet BP, Guislain A, van Alphen FPJ, Gomez-Eerland R, Schumacher M, et al. c-Myc-Driven Distinct Homing Potentials and Effector Responses. *J Immunol* (2018) 200:4297–305. doi: 10.4049/jimmunol.1801026

62. St. Paul M, Ohashi PS. The Roles of CD8+ T Cell Subsets in Antitumor Immunity. *Trends Cell Biol* (2020) 30:695–704. doi: 10.1016/j.tcb.2020.06.003

63. Costimulation Through TLR2 Drives Polyfunctional CD8+ T Cell Responses. *J Immunol* (2016) 196:3695–705. doi: 10.4049/jimmunol.1501997

64. Salerno F, Paolini NA, Stark R, von Lindern M, Wolkers MC. Distinct PKC-Mediated Posttranscriptional Events Set Cytokine Production Kinetics in Export Proteins, Aly and CLIP29, to Assemble the TREX Complex. *Genes Dev* (2010) 24:2043–53. doi: 10.1101/gad.1899610

65. Salerno F, Freen-van Heeren JJ, Guislain A, Nicolet BP, Wolkers MC. Costimulation Through TLIR2 Drives Polyfunctional CD8+ T Cell Responses. *J Immunol* (2019) 202:714–23. doi: 10.4049/jimmunol.1801026

66. Salerno F, Guislain A, Cansever D, Wolkers MC, TLIR-Mediated Innate Production of IFN-γ by CD8+ T Cells Is Independent of Glycolysis. *J Immunol* (2016) 196:3695–705. doi: 10.4049/jimmunol.1501997

67. Salerno F, Paolini NA, Stark R, von Lindern M, Wolkers MC. Distinct PKC-Mediated Posttranscriptional Events Set Cytokine Production Kinetics in Export Proteins, Aly and CLIP29, to Assemble the TREX Complex. *Genes Dev* (2010) 24:2043–53. doi: 10.1101/gad.1899610

68. Salerno F, Freen-van Heeren JJ, Guislain A, Nicolet BP, Wolkers MC. Costimulation Through TLIR2 Drives Polyfunctional CD8+ T Cell Responses. *J Immunol* (2019) 202:714–23. doi: 10.4049/jimmunol.1801026

69. Salerno F, Guislain A, Cansever D, Wolkers MC, TLIR-Mediated Innate Production of IFN-γ by CD8+ T Cells Is Independent of Glycolysis. *J Immunol* (2016) 196:3695–705. doi: 10.4049/jimmunol.1501997
